Welcome to our dedicated page for Natera SEC filings (Ticker: NTRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Natera, Inc. (NASDAQ: NTRA) is a medical laboratories company focused on cell-free DNA testing and precision medicine in oncology, women’s health, and organ health. As a publicly traded issuer on the Nasdaq Stock Market LLC (Nasdaq Global Select Market), Natera files periodic and current reports with the U.S. Securities and Exchange Commission (SEC), which provide insight into its operations, financial condition, and material events.
On this SEC filings page, Stock Titan aggregates Natera’s regulatory documents, such as current reports on Form 8-K. For example, a recent Form 8-K filing describes the company’s release of quarterly financial results and an accompanying investor presentation, and confirms that Natera’s common stock, par value $0.0001 per share, is registered under the symbol NTRA on Nasdaq. These filings help investors understand how test volumes, revenue trends, and other operational metrics relate to Natera’s diagnostic and research activities.
Stock Titan enhances these filings with AI-powered summaries that explain key sections in accessible language, helping users interpret complex disclosures without replacing the original documents. Real-time updates from the SEC’s EDGAR system ensure that new Natera filings are added promptly, whether they involve earnings announcements, significant collaborations, or other reportable events.
Users interested in Natera’s precision medicine business can use this page to review historical and recent filings, track how the company discusses its oncology, women’s health, and organ health portfolios over time, and monitor material developments affecting NTRA. For deeper analysis, AI-generated highlights point to important items within lengthy filings so readers can focus on sections most relevant to their research or investment questions.
Form 144 Notice of Proposed Sale filed by Natera insider indicates planned sale of 19,908 shares of common stock with an aggregate market value of $3,335,585.40. The sale is scheduled for June 18, 2025, to be executed through Morgan Stanley Smith Barney LLC on NASDAQ.
The securities were originally acquired as Restricted Stock Units from the issuer on September 21, 2020. The seller, Daniel Rabinowitz, has conducted three previous sales in the past 3 months totaling 3,867 shares with gross proceeds of $566,033.98:
- April 28, 2025: 1,993 shares for $303,299.52
- April 21, 2025: 470 shares for $68,407.52
- March 31, 2025: 1,404 shares for $194,326.94
The company currently has 136,546,580 shares outstanding. This proposed sale represents approximately 0.015% of total shares outstanding.